Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Drug discovery

The druggability of SH2 domains unmasked

Nature Chemical Biology volume 20, pages 271–272 (2024)Cite this article

Subjects

Developing inhibitors for SH2 domains is challenging due to their shallow pockets and highly charged ligands. Structure-guided drug design has enabled the discovery of a cell-permeable covalent inhibitor of the SOCS2 SH2 domain, a key regulator of cytokine signaling pathways.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Development of a cell-permeable ligand targeting the SH2 domain of the cytokine receptor signaling regulator SOCS2.

References

  1. Schlessinger, J. Cell 103, 211–225 (2000).

    Article  CAS  PubMed  Google Scholar 

  2. Hunter, T. Cold. Spring Harb. Perspect. Biol. 6, a020644 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Jin, J. & Pawson, T. Philos. Trans. R. Soc. Lond. B Biol. Sci. 367, 2540–2555 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Makukhin, N. & Ciulli, A. RSC Med. Chem. 12, 8–23 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ramachandran, S. et al. Nat. Commun. 14, 6345 (2023).

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  6. Palmer, D. C. & Restifo, N. P. Trends Immunol. 30, 592–602 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Liu, X. & Ciulli, A. ACS Cent. Sci. 9, 1269–1284 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Physiological Chemistry, Philipps-University of Marburg, Marburg, Germany

    Oliver Hantschel

Authors
  1. Oliver Hantschel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oliver Hantschel.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hantschel, O. The druggability of SH2 domains unmasked. Nat Chem Biol 20, 271–272 (2024). https://doi.org/10.1038/s41589-024-01557-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41589-024-01557-w

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research